OBJECTIVES: Determine hypertension-related costs and cost-effectiveness ratios of pharmaceutical treatment for patients with hypertension in Greece METHODS: Data was derived from the PharmacoECOnomic Assessment of Prognostic Risk Occupational Survey (ECON-APROS), a cross-country prospective study. The sample included individuals 30-75 yrs old, diagnosed with hypertension (Systolic Blood Pressure>140 mmHg and/or Diastolic Blood Pressure>90mmHg), who were treated and monitored for a period of 1 year after the diagnosis. Patients were separated in two subgroups: a) those with uncomplicated hypertension (N=1243) and b) those with complications e.g. CVD, CHD, MI etc. (N=122). Demographic, clinical and socioeconomic information was collected. Cost analysis was based on the direct cost estimations and the measurement of the effectiveness was based on the absolute reductions in the mean SBP for each subgroup after 1 year of treatment. The perspective of the Greek NHS was taken. Tariffs are referred to 2006 prices and costs are expressed in Euros. RESULTS: Mean direct cost per patient suffering from uncomplicated hypertension was estimated at 687 € per year while for the second subgroup was significantly higher at 1771 € per year. Mean reduction in the patients' Systolic Blood Pressure was 32.58mmHg for the first subgroup and 34.38mmHg for the second. Cost-effectiveness ratios for each subgroup were estimated at 21.1 €/mmHg and 51.7 €/mmHg, respectively, for every 1 mmHg lowering of the Systolic Blood Pressure. CONCLUSION: The long term consequences of untreated hypertension are both life-threatening, for the patients, as well as resource-consuming for the health care system. The ECON-APROS study has demonstrated that, besides the importance clinical-wise to treat hypertensive patients in their early stages of the disease, it is also cost-effective for the Greek healthcare setting